Dr. Chiriva Internati has served as our Chairman and Chief Executive Officer since February 2018 and as our President since October 2019. Between December 2012 and September 2019, he served as Chief Scientific Officer. Between December 2012 and August 2018, he also served as our Director of Clinical Translation Research. Dr. Chiriva Internati has been an Associate Professor at the MD Anderson Cancer Center in Houston, Texas since August 2019. Prior to that, he served as an Associate Professor at Texas Tech University Health Sciences Center from September 2013 to June 2017. His research has led to the identification of novel cancer-testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. This led to the development of the bioinformatic software Diamond CancerSplice, which is a key core platform of our company, leading to the discovery and prioritization of isoform antigens via insilico system. Dr. Chiriva Internati earned a PhD in Immunology from the University of Nottingham, United Kingdom. He also earned a PhD in Morphological Science from the Universit`a degli Studi di Milano, Italy, and a Doctoral Degree in Biological Sciences from the University of Milan, Italy. Dr. Chiriva- Internati was a PostDoctoral Fellow in Immunology at the University of Arkansas for Medical Sciences, earned a certificate in Artificial Intelligence from MIT Sloan School of Management and earned a certificate in Financial Technology from Oxford Saıd Business School.
After a PhD in Molecular and cellular aspect of Biology, working on the induction of DNA double Strand during the Class switching process in B cells, Sara started to work on Life Sciences companies such as Merck, ThermoFisher scientific as Technical expert and Sales Specialist covering cell analysis, molecular biology and spatial genomic analysis. Since one year, Sara joined Lunaphore as European Sales Specialist covering microfluidic solutions for tissue analytics
.jpg)
Priyanka Koti is a Bioink Production Engineer at CELLINK, a leading company in bioprinting and biotechnology. Her day-to-day includes producing and distributing high-quality biomaterials to customers across the globe. She joined CELLINK in 2019 after completing her MEng in Biomedical Engineering at Cornell University. At Cornell, Priyanka worked on the development of a universal printhead to evaluate cell viability in real time. Prior to her graduate studies, she researched cardiac tissue engineering and bioprinting and received her BS in Biomedical Engineering at The George Washington University.
Dr. Phillips is the Senior Manager of the North American Field Applications Team at Ultivue in Cambridge, MA. She first joined Ultivue in June of 2018 prior to the release of Ultivue’s first commercial product. During her time at Ultivue, Bonnie began as a Field Application Scientist, and Prior to working at Ultivue, she was a postdoctoral Fellow at University of North Carolina, Chapel Hill where she gained extensive experience with fluorescent immunohistochemistry assays and imaging. She has a Ph.D. in Biomedical Sciences with a focus on immunology and infectious disease from Tulane University in New Orleans, LA.
Reed has over 20 years of experience in the diagnostic and pharmaceutical industries commercializing innovative products and solutions that are at the leading edge of technology. Reed sees the rapidly growing field of combining precision NGS-based diagnostics, including liquid biopsy, with targeted therapeutics and immunotherapies as one of the keystone opportunities of making cancer a manageable condition. The knowledge we have of the genome is growing rapidly, and leveraging these insights in the clinic is transforming the cancer care landscape. Reed has a degree in biochemistry from the University of Michigan.
She has 25 years of experience in design, analysis and publication of clinical trials in oncology. She graduated in Mathematics at the Université Catholique de Louvain, Louvain-la-Neuve, and in Biostatistics at the Hasselt University, in Belgium, and did her PhD at the Erasmus University in Rotterdam, The Netherlands. After 25 years developing cancer treatments mostly through late phase trials with the European Organisation for Research and Treatment of Cancer (EORTC), she joined IDDI to develop and apply her expertise to earlier development phases. She has a special interest in large pragmatic clinical trials, and in adaptive designs, when they bring efficiency gains that outperform their extra complexity.
Jingjing Zhu is a senior research scientist at the Ludwig Institute for Cancer Research and has 12 years of experience working in the anti-cancer therapeutical target discovery and therapy development field. After obtaining her Ph. D. in Biomedicine at KU Leuven, Belgium. She joined Ludwig Institute for Cancer Research, focusing on cancer immunotherapy and developing novel anti-tumor immune therapeutics.
Dr. Zhang is a technical specialist at Sino Biological Europe, where she provides technical support of our recombinant protein and antibody products, as well as the support of CRO services of recombinant protein production and antibody development for our customers. Before She joins our team in Frankfurt, Germany, September 2021, Dr. Zhang worked as a project leader in University of Lübeck, where she received her PhD Degree. Her research interests include protein structural biology, antiviral therapy, and virus-host interaction mechanisms.
Completed his master's in Biology and Synthetic Biology from the University of Münster. His work experience includes the successful completion of product and application development projects at several diagnostics labs, including BlueSens GmbH. With advanced knowledge on system, synthetic, biology, Robert overseas the research and development areas as Chief Scientific Officer at evorion biotechnologies GmbH.
George Weiner MD, is a physician, scientist and founder and CEO LIRECAP, inc, that is based on technology discovered in his laboratory at the University of Iowa where he serves as Director of the Holden Comprehensive Cancer Center, Professor of Internal Medicine and holds the Block Chair of Cancer Research. Weiner’s cancer research has been continually funded by the NCI since 1991. He received his undergraduate degree from Johns Hopkins University, his MD from The Ohio State University and training in Hematology, Oncology and Immunology at the University of Michigan before joining the faculty at the University of Iowa. Weiner has served in a number of leadership positions nationally. He is Past President of the Association of American Cancer Institutes and past chair of the NCI Committee that provides peer-review of the nation’s cancer centers. He currently chairs the External Advisory Boards for six other NCI designated cancer centers.
Dr. Todorov is a Lead Scientist within the Multiplexing team in the Pharma Services division at NeoGenomics. Her work focuses on developing assays to improve biomarker spatial analysis using the MultiOmyx multiplex-immunofluorescence (IF) platform. She earned her Ph.D. in developmental biology at the University of California, Irvine (UCI) followed by a postdoctoral fellowship studying tissue regeneration and stem cells at the University of California, San Francisco (UCSF). Prior to joining NeoGenomics, Courtney was a Senior Scientist at Advanced Cell Diagnostics where she developed novel RNAscope in-situ hybridization (ISH)-immunohistochemistry (IHC) based assays. Her combined experience has made her an expert in utilizing and developing histological IHC and ISH techniques to answer complex biological questions.
Kiave-Yune HoWangYin, PhD Research and Development Director. Kiave HoWangYin holds a PhD in Immunology / Oncology from the Paris 7 University (France). She worked for 5 years in the Center of Cardiovascular Research (Paris) as scientist in the field of inflammation and angiogenesis. She published more than 10 papers in peer-reviewed international journals in oncology and inflammation.
Miten is an Assistant Research Scientist at the University of California Santa Cruz. He did his PhD in Biomolecular Engineering and Bioinformatics at UC Santa Cruz in the nanopore group. His prior work and research interests include developing biological methods and software for: 1) analyzing genomics data; 2) long read sequencing of DNA and RNA; 3) resolving homopolymers and base modifications; 4) the nanopore MinION and PromethION sequencing platforms; and 5) sequencing and analysis of different classes of RNA (mRNA, rRNA, tRNA, non-coding RNA). His long term interests include combining sequence and structure information from DNA (genomics), RNA (coding and non-coding), and proteins, to better understand genome organization and function.
Lindy is a Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed a panel of mabs recognised tumour associated glycans and has pioneered a new antibody engineering technology which enhances the avidity of mabs, termed Avidimabs. This has been applied to the anti-glycan mabs resulting in direct killing mabs. These mAbs are also good at drug delivery making strong ADCs with duocarmycin and PBD payloads. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease-free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer-reviewed publications and is also the inventor of 66 patents. She was awarded the Waldenstrom Prize for cancer Immunotherapy in 2019.
Paul Keown is Professor of Medicine and Director of Immune Sciences at the University of British Columbia and Lead of the Genome Canada Transplant Consortium. He received his MD and DSc degrees in the UK with post-doctoral research in immunology and clinical medicine in Europe and Canada.
Karen Sherwood is Lead Genome Scientist and Director of Scientific Programs for the Genome Canada Transplant Consortium. She received her PhD degree in Edinburgh with post-doctoral research in gene sequencing and neuropathology in the UK and Canada.
Ning is a bioinformatics scientist at Arcus Biosciences, where he is responsible for drug discovery, target identification, and indication prioritization in multiple immune-oncology drug programs. Notably, Ning pioneered the 3D organoids based drug response prediction technology, which largely facilitated cancer model selection. During his PhD, he studied with Professor Alexander Hoffmann at UCLA, where he built up computational framework to identify synergy between key immune response signaling pathways in macrophage. Ning holds a PhD in Bioinformatics from UCLA.
Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.
As Director of Biomarkers at Larvol, Dr. Gramling leverages his years of experience in research, technology development, and healthcare industry. As a researcher, he has examined novel pathways ranging from the impact of coagulation factors on breast cancer to modulators of Ras and Myc signaling in lymphoma. Outside of research, Dr. Gramling has focused on building the teams and tools to serve markets ranging from clinical trial study start up and health economics outcomes research to benefits management and pharmaceutical competitive intelligence. With Larvol’s platform Veri, Dr. Gramling is developing solutions and analytic tools around predictive biomarkers in oncology.
Russell LaMontagne is co-founder and Chief Executive Officer of Boston Immune Technologies and Therapeutics, Inc. Russell has overseen all aspects of the development of BITT’s antagonist platform including the company’s lead candidates targeting TNFR2 and CD40. In addition to BITT, for the last ten years he has been organized a working group in partnership with Massachusetts General Hospital to promote clinical trials and new indications for the BCG vaccine. Prior to BITT Russell was president of Corinth Group, a boutique healthcare consultancy. Russell has a BS in Biology from the University of Massachusetts at Amherst and MA from Yale.
Dr John Maudsley trained at UCL with Professor Avrion Mitchison and Professor Sir Marc Feldmann, during which time he was one of the first people to make monoclonal antibodies to T cells and T cell cytokines and use them to modulate immune responses. He post-doc-ed at the University of Warwick looking at immune responses to oncogenes and viruses and the mechanisms by which oncogenes and viruses inhibit immune responses. He lectured in Immunology at Coventry University. He is co-founder and CEO of Cancer Vaccines. Here he has developed an innovative allogeneic cellular vaccine for treating cancer that is undergoing clinical trials. He is also CEO/CSO of Revax developing disruptive technology for respiratory infection vaccines.
Melita Irving is originally from Canada and has been working in the field of T-cell engineering in Switzerland
for the past 15 years. Since 2013 she is a group leader at the Ludwig Institute for Cancer Research at the University of Lausanne.
Ann gained a PhD from Cambridge University studying inflammatory responses in vascular endothelial cells at the Babraham Institute. After training in microvascular biology with Professor Judah Folkman in Boston, she began her life-long interests in high endothelial venule (HEV) blood vessels and T-cell trafficking as a postdoctoral fellow with Professor Bill Ford at the University of Manchester. Ann gained an MRC Senior Fellowship in Manchester and moved to a PI position at the MRC National Institute for Medical Research in London where she began working on L-selectin/CD62L. Ann moved to Cardiff University as Reader and was awarded a personal chair as Professor of Cellular Immunity and Immunotherapy.
The Ager lab studies how T lymphocytes move around the body to protect against infection, control cancer progression and contribute to neurodegeneration such as in Alzheimer's disease. A major focus has been the regulation of L-selectin/CD62L expression by T lymphocytes and its impact on physiological and pathological T-cell recruitment from the bloodstream into tissues via specialised high endothelial venule (HEV) and inflamed blood vessels. Recent studies have revealed an essential role for L-selectin in the recruitment of killer T cells into flu-infected lungs for virus clearance (http://www.bbc.co.uk/news/uk-wales-south-east-wales-35373730). Current studies are testing whether manipulating L-selectin on cancer-killing T lymphocytes, such as CAR-T cells, increases their ability to seek out and destroy solid cancers.
As Chair of Forum and a Trustee of the British Society for Immunology (BSI) and a Council member of the International Union of Immunological Societies (IUIS) Ann is an advocate for Immunology to governments and other policy makers. Ann is also deputy chair of the BSI-NCRI alliance which brings together immunologists and oncologists who research, develop and use cancer immunotherapies to treat patients.
Corinne Danan is Veracyte’s General Manager, Biopharma, leading the company’s offerings to biopharmaceutical companies. She brings more than 25 years of executive experience in the pharmaceutical, life sciences and healthcare industries.
In 2015, she cofounded and was a member of the board of HalioDx, an immuno-oncology diagnostics company acquired by Veracyte in August 2021. At HalioDx, Corinne Danan led the creation and development of the Pharma business unit, bringing to the company’s biopharmaceutical partners various solutions to support better understanding of the tumor microenvironment within different phases of clinical trials.
Prior to HalioDx, Corinne Danan held senior positions at leading diagnostics companies, including Qiagen, Ipsogen, and Monogram Biosciences. Earlier in her career, she held various leadership positions at Eli Lilly.
Corinne Danan holds an MBA from INSEAD Business School.
Maik Pruess, Senior Field Application Scientist (FAS); Personalis, Germany
Since 2020: Senior Field Application Scientist (FAS); Personalis, Inc.
2018 – 2020: Field Application Specialist; Agena BioScience GmbH
2013 – 2018: Sr. Field Application Scientist & Prosigna Trainer EMEA, Nanostring, Inc.
Maik has done his diploma in Biochemistry from Berlin.
Stefan Glück, MD, PhD, FRCPC is medical oncologist and currently is VP, Head Oncology franchise in Medical affairs at Regeneron. He leads a fast growing team of internal experts in the field of Hematology and Oncology. Prior to that he was V.P. Global Medical Affairs, at Celgene Corporation since October 2014 until December 2019. He oversaw oncology activities worldwide, as well as the Immuno-Oncology program in solid tumors and hematology. He also contributed to activities of Celgene around Early Assets.
He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects. Before his move to Miami, Dr. Glück was Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, a Professor in the departments of oncology, medicine, pharmacology & therapeutics at the University of Calgary, Alberta, Canada, and Deputy Head, Dept. of Oncology at the University of Calgary. He completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology & bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto, Canada.
Dr. Glück was presented the “America’s Top Oncologists” 2008 award from Consumers’ Research Council of America, as well as “Best Doctors in America” honor since 2006, and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States.
